Archive
1321 articles, sorted by publication time.
The AUTUS valve can be resized after implantation using a balloon catheter, offering the possibility of fewer repeat open-heart surgeries for children with congenital heart disease. However, only two patients have undergone expansion so far, and whether the valve can maintain its function over the long term remains to be verified.
Tumor tissue removed during surgery may offer clues for subsequent treatment. An analysis across 26 centers shows outstanding long-term survival among patients who respond well to neoadjuvant immunotherapy and suggests a research direction for reducing postoperative medication; however, prospective trials are still needed to confirm who can safely receive less treatment.
Allowing trials to adapt as data accumulate and reducing the cost of repeatedly setting them up are central ideas behind a new U.S. research program. Whether this framework, spanning predictive models and community trial sites, can accelerate the evaluation of new drugs still needs to be demonstrated with reliable clinical evidence.
Phase 2 AMETHYST data offer longer-term treatment insights for patients who do not respond to or cannot tolerate antimalarial drugs; however, the latter part had no placebo control, and confirmation of efficacy and safety still awaits Phase 3 trials.
Can switching from repeated injections to oral treatment maintain the required drug exposure? The AZTOUND trial involving 88 adults met its primary endpoint, but full data have yet to be released, and treatment response and survival benefits cannot be inferred directly from this result.
For complex inflammatory diseases, OpenEvidence can provide information physicians find useful; however, full agreement with consultation conclusions was approximately 40–50%, and answers to the same question also changed over time.
GB-5267 enables patients’ own T cells to recognize MUC16 and incorporates IL-18 to address the tumor’s immunosuppressive environment. The first patient has received treatment, and the Phase 1 trial will first address safety and dosing questions.
A routine ECG could become an entry point for identifying hidden heart muscle disease. A Yale team is using image-based AI to help guide further testing, but clinical validation is still needed to establish whether screening performance translates into better patient outcomes.
For adults facing both weight and blood glucose problems, a dual receptor agonist offers new clinical evidence. But the striking figures assume continued treatment, and the ability to tolerate long-term use also shapes the practical significance of its efficacy.
When breast cancer develops resistance to endocrine therapy, how can disease control be maintained? The phase 3 evERA trial provides new evidence for an oral drug combination, but whether it can extend life remains to be answered by survival follow-up.
The noncovalent BTK inhibitor pirtobrutinib enters first-line treatment: a phase 3 trial shows that it delays disease progression compared with chemoimmunotherapy, but longer follow-up is needed to determine whether it extends overall survival.
A study in Nature shows that senescent cells not only sound the alarm through damaged mitochondria but also use acetyl-CoA to reshape chromatin and amplify pro-inflammatory secretion. Blocking citrate transport improved multiple measures in aged mice, but has not yet been tested in humans.